Our findings indicate that human, tumor-derived VEGF substantially triggers neovascularization in the investigated MDA-MB-231 human breast cancer model in mice and that a one-week bevacizumab monotherapy can be successfully applied to inhibit angiogenesis in this particular tumor model. This evidence concerns the gene VEGFA and breast cancer.